Excelsior Medical Co., Ltd. · TWSE:4104
Excelsior Medical — FY2021 Earnings Presentation
33 slides from Excelsior Medical's earnings presentation, Apr 28, 2022
Slide 1: Excelsior Medical Co., Ltd. Investor Conference
Excelsior Medical Co., Ltd. Investor Conference 2022/4/28
Slide 2: Disclaimer
Disclaimer This presentation is prepared according to the audited or reviewed financial statements by CPA and the financial figures hereby are based on IFRS, please refer to the published financial statements for full content. The presentation may contain forward-looking information and may differ m
Slide 3: Table of Contents
Table of Contents 1.公司概況(Corporate Overview) P.4 2.市場概況(Market Overview) P.8 3.營運概況(Business Overview) P.11 4.財務概況(Financial Overview) P.14 5.轉投資概況(Investment Overview) P.17 6.2022策略及展望(2022 Strategies and Outlook) P.23 7.補充資料(Appendix) P.26 3
Slide 4: Corporate Overview
Corporate Overview Chairman Group President Tony Fu “Dedication, Discipline, Innovation, Proactive” are the core values of Excelsior. “Human Healthcare” is the basis of medical service industry. Therefore, “Dedication” to our service target is what matters the most. We focus on public healthcare, us
Slide 5: The Most Valuable Total Healthcare Solution Provider among Asia
The Most Valuable Total Healthcare Solution Provider among Asia with Exceptional Investing and Operating Teams！ Excelsior Medical Co., Ltd. was established in 1988, Excelsior started with the distribution of hemodialysis equipments and supplies. Gradually transformed into integrated medical services
Slide 6: Revenue structure
Revenue structure Excelsior yearly consolidated sales is more than NT $ 6.5 billion in 2021, the primary revenue comes from Excelsior (Hemodialysis), Dynamic (Aesthetic Medical), Arich (Pharmaceutical Logistics) and others. According to the company’s function, the business type can be characterized
Slide 7: The Business Types
The Business Types Hemodialysis Aesthetic Medical Trading Business Medical Devices Medical Consumables Home Appliances Product Planning Sales Information Analysis Promotion Hemodialysis channel Pharma. Sales and Promotion Market Creative Aesthetic Medical channel Pharma. Distribution and Logistics M
Slide 8: Market Overview: Excelsior (Hemodialysis)
Market Overview Excelsior(Hemodialysis) Taiwan benefited from the implementation of the national health insurance system in 1995 and the hemodialysis technology and quality gradually mature, the patient's survival rate has gradually increased. According National Health Insurance Administration , as
Slide 9: Dynamic (Aesthetic Medical)
Dynamic(Aesthetic Medical) According to the Asian-Pacific Market Study issued by Medical Insight, Inc. in Mar. 2022, total Asian sales of all aesthetic products and equipment reached US$2.7 billion in 2020 and are expected to increase by 16.4% per year through 2025. Furthermore, aesthetic medical ma
Slide 10: Arich (Pharmaceutical Logistics)
Arich (Pharmaceutical Logistics) Medicines cover cost approximately 1/4 of National Health Insurance expenditures. In Taiwan, although demand for medication is growing, but the prices approved/reimbursed by NHI are declining. Consequently the multinational pharmaceutical companies keep on outsourcin
Slide 11: Business Overview: Excelsior (Hemodialysis)
Business Overview Excelsior(Hemodialysis) Unit: NTD in thousands Excelsior’s operating income was NT $ 344,234 thousands in 2021 and NT $ 319,114 thousands in 2020; the growth rate was 7.9%. The greater profit in 2021 than which of 2020 is increased because of the increase in sales of high-margin pr
Slide 12: Dynamic (Aesthetic Medical)
Dynamic(Aesthetic Medical) Unit: NTD in thousands Dynamic’s operating income were NT $ 160,418 thousands in 2021 and NT $ 140,848 thousands in 2020; the growth rate was 13.9%. Operating income increased compared with the prior year is due to the growth of lifestyle beauty products and treatment serv
Slide 13: Arich (Pharmaceutical Logistics)
Arich (Pharmaceutical Logistics) ARICH’s operating income was NT$ 54,430 Unit: NTD in thousands thousands in 2021 and NT$ 48,329 thousands in 2020; the growth rate was 12.6%. Mainly due to the decrease in sales and promotion revenue and the impact of the COVID-19 in 2021, but the increase in distrib
Slide 14: Financial Overview
Financial Overview Consolidated revenue Consolidated gross profit Unit: NTD in thousands Unit: NTD in thousands Consolidated operating Income Unit: NTD in thousands 14
Slide 15: Unit: NTD in thousands Unit: NTD in thousands
Unit: NTD in thousands Unit: NTD in thousands 15
Slide 16: Unit: NTD in thousands Unit : NTD in Dollars
Unit: NTD in thousands Unit : NTD in Dollars 16
Slide 17: Investment Overview: Hemodialysis channel – Excelsior Renal Service
Investment Overview Hemodialysis channel – Excelsior Renal Service Co., Limited &Jiate Excelsior Co., Ltd 【 Hemodialysis channel Introduction 】 Excelsior has entered into a joint venture with Fresenius which is the world's largest manufacturer of dialysis products, and has established long-term coop
Slide 18: Hemodialysis channel – Excelsior Renal Service Co., Limited
Hemodialysis channel – Excelsior Renal Service Co., Limited &Jiate Excelsior Co., Ltd ERS’s Profit after Tax Number of ERS channels (NTD in thousands) 18
Slide 19: Hemodialysis channels
Total % Area ERS channels channels Taipei keelung North 291 35 12.0% Central 202 45 22.3% New Taipei City South 196 21 10.7% other 38 1 2.6% Total 727 102 14.0% Taoyuan Hsinchu Miaoli Taichung Changhua Yilan Yunlin Nantou Chiayi Tainan Pingtung Kaohsiung Hemodialysis channels 19
Slide 20: Long-Term Care Channels – Asia Best Healthcare Co., Ltd.
Long-Term Care Channels– Asia Best Healthcare Co., Ltd. Xizhi Nursing Home 內部配置 【 Long-Term Care Channels Introduction 】 Excelsior combines the experiences and advantages in the medical industry, with innovative concepts to build higher service standards of long-term care channels. We provide Long T
Slide 21: Long-Term Care Channels – Asia Best Healthcare Co., Ltd.
Long-Term Care Channels– Asia Best Healthcare Co., Ltd. ABH’s Profit after tax (NTD in thousands) Number of ABH Beds 招大廳 21
Slide 22: Long-term care channels
Hospital/long-term care Hospital Beds 504 Long-term care channels Long-term care 2,732 Total 3,236 Xizhi keelung Taoyuan Taipei Ping-zhen New Taipei City Taichung Taichung Changhua Yunlin Kaohsiung Nantou Tainan Kaohsiung 22
Slide 23: 2022 Strategies and Outlook: Excelsior (Hemodialysis)
2022 Strategies and Outlook Excelsior(Hemodialysis) Long-Term Planning Backward integration of the Mid-Term Planning hemodialysis business through acquisition of a ⚫Externally, the Company will hemodialysis solution factory integrate medical resources, in Malaysia. After the follow-up introduce comp
Slide 24: Dynamic (Aesthetic Medical)
Dynamic(Aesthetic Medical) Long-Term Planning ✓ Market leader Mid-Term Planning ✓ Southeast Asia Market ✓ New Product Development ✓ Strategic Alliance ✓ Preventive Medicine ✓ Lifestyle Beauty Device ✓ Aesthetic Consumables ✓ Body Contouring Market Short-Term Plan Development ✓ Brand/Channel Expansio
Slide 25: Arich (Pharmaceutical Logistics)
Arich (Pharmaceutical Logistics) Long-Term Planning 1.Sales and Promotion A. To seek strategic partners and to expand the variety of Mid-Term Planning our products. B. To integrate Excelsior group’s 1.Sales and Promotion dialysis and long term care Actively looking for the centers and to enter into
Slide 26: Appendix: Balance Sheet
a 22== Appendix Balance Sheet Unit: In_ thousands NTD | __- 2020.12.31 =| 2021.12.31 __—i Current Assets 2,618,464 3,072,264 1,445,276 1,617,903 2,494,273 2,857,144 851,236 910,243 1,092,551 849,989 8,501,800 9,307,543 Non-current financial assets at fair value thr h 735,437 701,541 other comprehens
Slide 27: Liabilities and Equity
Unit: In thousands NTD 2020.12.31 2021.12.31 Liabilities Current Liabilities Short- term borrowings 404,498 479,966 Payables 882,266 947,530 Other payables 2,001,349 2,721,225 Other current liabilities 731,819 806,308 Total Current Liabilities 4,019,932 4,955,029 Non-Current Liabilities Other non- c
Slide 28: Statement of Comprehensive Income
Statement of Comprehensive Income Unit: In thousands NTD 2020 2021 Operating revenue 6,675,494 6,573,152 Operating costs 5,368,996 5,200,533 Gross Profit 1,306,498 1,372,619 Gross Margin 19.57% 20.88% Operating expenses 777,428 777,593 Operating Income 529,070 595,026 Non- operating income and expen
Slide 29: Cash Flows from Operating Activities
Unit: In thousands NTD 2020 2021 Profit before tax 829,383 873,736 Adjustments (98,489) (38,440) Cash Flows from Operating Activities Receivables 112,387 (175,153) Other receivables 196,476 (363,772) Inventories (36,471) (121,871) Payables (177,012) 65,264 Other payables 191,162 719,867 Income taxes
Slide 30: Statements of Cash Flows
Statements of Cash Flows Unit: In thousands NTD | 2020 | 2021S | assets at amortized (620,951) (680,170) Proceeds from disposal of financial assets at 365,699 764,031 amortized cost Acquisition of property, plant and equipment (30,716) (164,690) Proceeds from disposal of property, plant 285 94 and e
Slide 31: Statements of Cash Flows: Financing Activities
3 1 FS] eee Excelsior Healthare Group, Statements of Cash Flows Unit: In thousands NTD Cash Flows from Financing Activities (Decrease) Increase in short- term borrowings Repayments of long- term borrowings Cash dividends paid Capital increased by cash Net Cash Flows used in Financing Activities Effe
Slide 32: Growing up with Long-term partners
Growing up with Long-term partners Excelsior has been operating for 30 years, accumulated core competitiveness with new ideas created, new models to integrate various professional medical fields. Excelsior will keep taking root in the Asia market, the business scope includes Taiwan, Hong Kong, China
Slide 33: Growing up with Long-term partners
Growing up with Long-term partners Excelsior has been operating for 30 years, accumulated core competitiveness with new ideas created, new models to integrate variously professional medical fields. Excelsior will keep take root in the Asia market, the business scope includes Taiwan, Hong Kong, China